GlycoEra AG announced today key appointments of biotech industry leaders to its Board of Directors, including Georges Gemayel, Ph.D., as Chair, as well as Philippe Dro, Ph.D., M.B.A., and Kush Parmar, M.D., Ph.D.
Schlieren, Switzerland & Boston, Massachusetts USA – July 12, 2022
Dr. Ganguly brings nearly 25 years of experience in biopharmaceutical research and development across a variety of therapeutic areas including autoimmune diseases, inflammation, and oncology, among others.
Schlieren, Switzerland & Boston, Massachusetts USA – June 16, 2022
Dr. Kaundinya has been a member of the GlycoEra AG Board of Directors since the company’s inception in 2020, helping the team define corporate strategy and raise Series A capital of more than $49 million (CHF 45 million).
Schlieren, Switzerland & Boston, Massachusetts USA – May 3, 2022
GlycoEra AG announced today the close of a CHF 45 million ($49 million) Series A financing round, co-led by renowned US and European life science investors, 5AM Ventures, Roche Venture Fund and Sofinnova Partners.
Schlieren, Switzerland – November 5, 2021
GlycoEra AG announced today its incorporation with the purpose of leveraging a proprietary glycoengineering platform to develop a pipeline of novel biologics for inflammatory disease, autoimmune disorder and immuno-oncology indications.
Schlieren, Switzerland – January 5, 2021